Abstract
Paclitaxel was administered as a 24-h continuous infusion at 250 mg/m2 in this Phase II trial in patients with adenocarcinoma of the colon or rectum. Nineteen patients were evaluated for toxicity and 15 were assessable for response. There were no complete or partial responses, and toxicity present was primarily neutropenia. This study found that paclitaxel as a single agent does not have activity in adenocarcinoma of the colon or rectum.
Original language | English (US) |
---|---|
Pages (from-to) | 750-754 |
Number of pages | 5 |
Journal | American Journal of Therapeutics |
Volume | 3 |
Issue number | 11 |
DOIs | |
State | Published - Nov 1996 |
Externally published | Yes |
Keywords
- colon cancer
- paclitaxel (Taxol)
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)